ATRA - Atara Biotherapeutics Inc
IEX Last Trade
7.56
0.500 6.614%
Share volume: 78,556
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$7.06
0.50
7.08%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-08 | 2023-02-08 | 2023-05-08 | 2023-08-08 | 2023-11-01 | 2024-03-28 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 436.121 M | 368.316 M | 376.420 M | 302.083 M | 246.439 M | 188.788 M | 165.504 M | 165.272 M | |
| Current Assets | 346.984 M | 283.046 M | 295.080 M | 224.182 M | 172.320 M | 118.696 M | 101.869 M | 106.434 M | |
| Inventories | 0.000 | 0.000 | 1.586 M | 5.340 M | 7.861 M | 6.591 M | 9.706 M | 16.084 M | |
| Other Current Assets | 13.690 M | 16.047 M | 10.308 M | 12.892 M | 10.164 M | 9.388 M | 6.184 M | 8.131 M | |
| Short Term Investments | 13.690 M | 16.047 M | 10.308 M | 12.892 M | 10.164 M | 9.388 M | 6.184 M | 8.131 M | |
| Total Receivables | 637.000 K | 249.000 K | 40.221 M | 397.000 K | 507.000 K | 163.000 K | 34.108 M | 35.834 M | |
| Current Cash | 331.311 M | 265.404 M | 242.819 M | 205.407 M | 153.642 M | 102.408 M | 51.725 M | 46.239 M | |
| Total Non-current Assets | 89.137 M | 85.270 M | 81.340 M | 77.901 M | 74.119 M | 70.092 M | 63.635 M | 58.838 M | |
| Property Plant Equipment | 8.328 M | 7.270 M | 6.300 M | 5.852 M | 5.349 M | 4.628 M | 3.856 M | 2.989 M | |
| Other Assets | 80.809 M | 78.000 M | 75.040 M | 72.049 M | 68.770 M | 65.464 M | 59.779 M | 55.849 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 436.121 M | 368.316 M | 376.420 M | 302.083 M | 246.439 M | 188.788 M | 165.504 M | 165.272 M | |
| Total liabilities | 178.642 M | 181.203 M | 249.780 M | 237.123 M | 238.985 M | 239.626 M | 264.735 M | 263.580 M | |
| Total current liabilities | 65.688 M | 72.244 M | 78.916 M | 67.876 M | 74.552 M | 79.089 M | 142.226 M | 180.690 M | |
| Accounts Payable | 12.799 M | 11.296 M | 6.871 M | 5.068 M | 4.138 M | 6.511 M | 3.684 M | 2.854 M | |
| Other liabilities | 48.955 M | 47.887 M | 112.800 M | 114.329 M | 112.679 M | 112.029 M | 76.816 M | 40.693 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 63.999 M | 61.072 M | 58.064 M | 54.918 M | 51.754 M | 48.508 M | 45.693 M | 42.197 M | |
| Other liabilities | 48.955 M | 47.887 M | 112.800 M | 114.329 M | 112.679 M | 112.029 M | 76.816 M | 40.693 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 257.479 M | 187.113 M | 126.640 M | 64.960 M | 7.454 M | -50.838 M | -99.231 M | -98.308 M | |
| Common stock | 101.601 M | 102.423 M | 103.210 M | 103.969 M | 105.091 M | 106.401 M | 108.187 M | 140.587 M | |
| Retained earnings | -1.534 B | -1.618 B | -1.693 B | -1.768 B | -1.839 B | -1.909 B | -1.969 B | -2.001 B |